Nipocalimab-aahu is a human immunoglobulin G1 monoclonal antibody that binds with high affinity to the neonatal Fc receptor, resulting in the reduction of circulating IgG levels.

On Wednesday, the U.S. Food and Drug Administration (FDA) granted approval for IMAAVY™ (nipocalimab-aahu), Johnson & ...

Roivant Sciences secures $5.2B for advancing late-stage drugs like IMVT-1402 & brepocitinib. Click here to read an analysis ...

According to Shruti K Bhardwaj, Chief Clinical Nutritionist at Zydus Hospitals, Thaltej, Ahmedabad, “The thyroid gland is deeply dependent on specific nutrients to function optimally. Even with ...

MG-ADL scores improved, indicating enhanced daily functioning for patients with myasthenia gravis. Limitations include potential coding errors, selection biases, and missing clinical data ...

Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients who have anti-acetylcholine receptor antibody-positive myasthenia gravis ...

A key secondary endpoint was change from baseline in Quantitative Myasthenia Gravis scale (QMG) score at week 26 in the combined patient population. Results show that patients administered Uplizna ...

Ultomiris (ravulizumab-cwvz) is a brand-name infusion prescribed for myasthenia gravis. This article covers topics such as side effects, dosage, and how Ultomiris works. Ultomiris is an ...

My name is Tasha White, and I was diagnosed with myasthenia gravis at the young age of six years old. Myasthenia gravis, or MG for short, is a chronic autoimmune disorder that causes weakness in the ...

Nicholas J. Silvestri, MD, describes how this year’s AAN meeting highlighted significant advances in myasthenia gravis, including improved diagnostics through cell-based assays that enhance ...